Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?

Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.1% gain over the past four weeks.The stock rallied after the company announced that its partner Biogen had made an unsolicited, non-binding proposal offer to acquire SAGE shares that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan 10.This company is expected to post quarterly loss of $1.44 per share in its upcoming report, which represents a year-over-year change of -161.8%. Revenues are expected to be $13.96 million, down 82.1% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Sage Therapeutics, the consensus EPS estimate for the quarter has been revised 2.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on SAGE going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Sage Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Zai Lab Limited Unsponsored ADR (ZLAB), closed the last trading session 0.4% lower at $25.21. Over the past month, ZLAB has returned -3.9%.For Zai Lab Limited, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.67. This represents a change of +31.6% from what the company reported a year ago. Zai Lab Limited currently has a Zacks Rank of #3 (Hold).Free: 5 Stocks to Buy As Infrastructure Spending SoarsTrillions of dollars in Federal funds have been earmarked to repair and upgrade America’s infrastructure. In addition to roads and bridges, this flood of cash will pour into AI data centers, renewable energy sources and more.In, you’ll discover 5 surprising stocks positioned to profit the most from the spending spree that’s just getting started in this space.Download How to Profit from the Trillion-Dollar Infrastructure Boom absolutely free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sage Therapeutics, Inc. (SAGE): Free Stock Analysis Report Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks